Invasive Fungal Infection Clinical Trial
Official title:
Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates
The pharmacokinetics of caspofungin are expected to be different in ICU patients compared to non-ICU patients. The investigators will determine caspofungin concentrations in 20 ICU patients, who will get caspofungin as standard care. Full PK curves will be taken on day 3 and a limited PK curve on day 7, trough levels will be taken daily.
The pharmacokinetics of caspofungin are expected to be different in ICU patients compared to non-ICU patients and healthy volunteers due to underlying disease(s). Therefore, extrapolation of data from healthy volunteers and non-ICU patients is not possible. To be able to include 20 patients within the study duration, a multi-centre approach is necessary. Patients will receive standard care, as stated in the SPC or according to local protocols. Blood sampling for PK analysis will be retrieved through a central venous catheter. Approximately 60mL will be drawn in total for this study. Patients will be monitored daily during the treatment period for adverse events of the study drug. Although steady state of caspofungin will be achieved after approximately 14 days of treatment, full PK curves will be taken on day 3. As probably not all patients included will be treated with caspofungin for 14 days, taking full PK curves on day 14 is considered not feasible. These two moments of PK analysis will enable the determination steady state and enable the determination of intra-individual variability. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01888458 -
Antifungal Prophylaxis With Micafungin After Cord Blood Allogeneic Stem Cell Transplantation (MycaCOORD)
|
Phase 2 | |
| Completed |
NCT00412893 -
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
|
Phase 3 | |
| Completed |
NCT03066011 -
Registry of Patients Treated With Systemic Mold-Active Triazoles
|
||
| Completed |
NCT04004078 -
An Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDM
|
||
| Completed |
NCT01576653 -
Prospective Clinical Evaluation of Beta-D-Glucan Assay in Blood and BAL
|
N/A | |
| Enrolling by invitation |
NCT02510053 -
Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit
|
N/A | |
| Completed |
NCT01198236 -
Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection
|
Phase 4 | |
| Recruiting |
NCT06137690 -
Factors on Therapeutic Drug Monitoring and Safety of Voriconazole in Critically Ill Elderly Patients
|
||
| Completed |
NCT01783379 -
Pharmacokinetics of Micafungin in Patients Intensive Care Unit
|
||
| Recruiting |
NCT03149562 -
Association of Plasma Transfusions and Invasive Fungal Infection
|
||
| Recruiting |
NCT04665037 -
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
|
Phase 2 | |
| Terminated |
NCT01148160 -
Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy
|
N/A | |
| Withdrawn |
NCT01185405 -
Voriconazole Plasma Level in Intensive Care Unit (ICU) Patients
|
N/A | |
| Completed |
NCT00893555 -
Pharmacologic Optimization of Voriconazole
|
Phase 3 | |
| Unknown status |
NCT00460330 -
Evaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCT
|
N/A | |
| Completed |
NCT02823132 -
Study of the Level of a Protein Which Could Predict the Development of a Fungal Infection in Patients With Acute Leukemia
|
N/A |